Filgrastim

Evidence Level: L4

Predicted Indications: 10

Filgrastim
Filgrastim: From Neutropenia to Primary Release Disorder of Platelets

## Pharmacist Assessment Report

Filgrastim: From Neutropenia to Primary Release Disorder of Platelets

One-Sentence Summary

Filgrastim (recombinant human G-CSF) is originally used to treat neutropenia and to mobilize peripheral blood stem cells prior to transplantation. TxGNN predicts a possible effect on Primary Release Disorder of Platelets with a very high model score (99.998%), but the supporting evidence — 14 clinical trials and 1 publication — consists almost entirely of transplant-support studies in which filgrastim was used incidentally for stem cell mobilization, not as a treatment targeting platelet release function.

Quick Overview

Item	Content
Original Indication	Neutropenia / peripheral blood stem cell mobilization (drug’s known pharmacological use; no formal TFDA label text is available in this evidence pack)
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	99.998%
Evidence Level	L4
Market Status (Taiwan)	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known pharmacology, filgrastim is a recombinant G-CSF that stimulates proliferation and differentiation of granulocyte precursors and mobilizes hematopoietic stem cells — it is not known to act on platelet dense-granule or alpha-granule secretion pathways, which are the defective mechanisms in primary platelet release disorders.

The evidence pack’s own mechanistic assessment is explicit on this point: there is no known direct pharmacological link between G-CSF signaling and platelet granule release. The reviewers hypothesize that TxGNN’s very high score (rank 48 of all candidate diseases) likely reflects an indirect knowledge-graph connection through “stem cell transplantation” nodes rather than a genuine pharmacological relationship.

Consistent with this, none of the 14 retrieved clinical trials or the single retrieved publication studied filgrastim as a treatment for platelet release disorders — they are transplant, GVHD-prophylaxis, or unrelated-condition studies in which filgrastim appears only as a supportive stem-cell-mobilization agent. This pattern supports treating the prediction as model-driven rather than mechanism-driven.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00245037	Phase 1/2	Completed	147	Non-myeloablative allogeneic HSCT for hematologic malignancies; filgrastim used for stem cell mobilization/support, not targeted at a platelet disorder (graded low relevance)
NCT01335932	Phase 2	Completed	160	RCT of ganciclovir/valganciclovir for CMV reactivation prevention in respiratory failure; filgrastim not the study drug (graded low relevance)
NCT04047628	Phase 3	Recruiting	156	AHSCT vs. best available therapy for treatment-resistant relapsing MS; general transplant context, no link to platelet release function (graded low relevance)
NCT00043979	Phase 2	Completed	60	Allogeneic/syngeneic stem cell transplant for high-risk pediatric sarcomas; filgrastim as supportive care only
NCT00076752	Phase 2	Completed	9	Autologous HSCT for severe systemic lupus erythematosus; filgrastim used for stem cell mobilization
NCT00923364	Phase 2	Completed	19	Reduced-intensity HSCT for patients with GATA2 mutations; filgrastim as supportive agent
NCT00354172	Phase 2	Terminated	16	Umbilical cord blood transplant with NK cells for myeloid leukemia; filgrastim as supportive agent
NCT06859424	Phase 2	Recruiting	358	Platform trial of post-transplant cyclophosphamide-based GVHD prophylaxis after mismatched unrelated donor PBSCT; filgrastim as supportive agent
NCT05436418	Phase 1/2	Recruiting	260	Dose-finding for post-transplant cyclophosphamide GVHD prophylaxis after reduced-intensity PBSCT; filgrastim as supportive agent
NCT02646098	Phase 2	Completed	64	CD34+ selected vs. unselected autologous SCT in advanced mantle cell/DLBCL lymphoma; filgrastim as supportive agent

(4 additional lower-relevance trials in the evidence pack are omitted here; none directly studied platelet release function.)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29770133	2018	Review/Observational	Frontiers in Immunology	G-CSF mobilization in healthy donors preferentially mobilizes lymphocyte subsets during peripheral blood stem cell collection; describes G-CSF immunomodulatory effects in donors, not disease-specific evidence for a platelet release disorder

Safety Considerations

A Blocking-severity data gap exists: TFDA label warnings and contraindications for filgrastim have not been retrieved, which prevents this candidate from entering the S1 safety pre-assessment stage. No drug interaction data was found (query returned no results). Please refer to the SmPC/TFDA label for safety information once retrieved.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L4 (mechanism/preclinical-adjacent at best), no trial or publication directly studied filgrastim for this indication, and the evidence pack’s own mechanistic review concludes there is no plausible pharmacological link — the high TxGNN score likely reflects an indirect knowledge-graph artifact. A Blocking safety data gap also prevents progression to the S1 safety stage.

To proceed, the following is needed:

TFDA label warnings/contraindications for filgrastim (Blocking gap, DG001)
Confirmed mechanism of action via DrugBank API (High-severity gap, DG002)
Direct pharmacological or preclinical evidence linking G-CSF signaling to platelet granule release
Clinical studies specifically enrolling patients with primary platelet release disorders, rather than incidental filgrastim use in transplant-support settings
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.